Drugs for Neurodegenerative Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (15 March 2014) | Viewed by 351
Special Issue Editors
Interests: neuropharmacology; neurophysiology
Special Issue Information
Dear Colleagues,
Patients diagnosed with neurodegenerative diseases in the form of dementia (as in Alzheimer’s disease) or motor impairment (such as Parkinson’s disease) undergo lifelong drug treatments. At present, these drugs act only modestly to either deter the progression of the disease or to alleviate the associated symptoms. Despite the significant progress that has been made over the years to develop more target-specific drugs based on the known pathophysiological mechanisms underlying the diseases, research still falls short of curing the diseases completely. In this Special Issue of Drugs for Neurodegenerative Diseases, articles describing the current treatment strategies of various neurodegenerative diseases will be invited for submission. Where appropriate, contributions are also encouraged to discuss novel treatment potentials for selected diseases. It is envisioned that with this Special Issue compilation, researchers in the field will be able to formulate new ideas in their future works on drug design and development.
Prof. Dr. Willmann Liang
Prof. Dr. David Tai Wai Yew
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alzheimer’s disease
- vascular dementia
- parkinson’s disease
- huntington’s disease
- amyotrophic lateral sclerosis
- acetylcholine
- dopamine
- glutamate
- symptomatic treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
